New Drugs for Genetic Disorders Coming Down the Pipeline, 2019 : Researchmoz

Researchmoz added Most up-to-date research on "Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease" to its huge collection of research reports.

The genetic disorders therapy area consists of indications that arise because of an abnormality in a person’s DNA. This report focuses on the key therapy area indications of cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), lysosomal storage disease (LSD) and paroxysmal nocturnal hemoglobinuria (PNH).

FREE| Request Sample is Available at: https://www.researchmoz.us/enquiry.php?type=S&repid=1509385

Genetic disorders are frequently inherited from an individual’s parents but can also arise because of a new (de novo) mutation. The treatment landscape for genetic disorders is dominated commercially by orphan drugs for the treatment of rare genetic disorders.

Overall, 1,390 products are being actively developed in the genetic disorders pipeline. The pipelines of CF, DMD, LSD and PNH contain 163, 109, 174 and 24 products, respectively. The pipeline is dominated by targeted therapies that aim to treat the underlying cause, which is often specific to the particular indication.

Scope

Global revenue from the genetic disorders market is forecast to increase from $19.6 billion in 2016 to $47.7 billion in 2023, at a compound annual growth rate of 13.55%. What is driving this growth?
The leading companies in terms of market share are Alexion, Sanofi, Shire and Vertex. Which of these are forecast to experience the largest growth?
There are new approvals and late-stage products set to enter the market during the forecast period. Which drugs will achieve blockbuster status?
The market has been dominated by complement system inhibitors and enzyme replacement therapies. To what extent will these classes of drugs and others dominate the market over the forecast period?
There are 1,390 genetic disorders products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
Genetic disorders clinical trials have an overall attrition rate of around 93%, what can companies do to maximize their chance of success?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-genetic-disorders-drugs-market-to-2023-a-rapidly-growing-treatment-landscape-driven-by-targeted-complement-system-inhibitors-and-enzyme-replacement-therapies-to-treat-pnh-and-lysosomal-storage-disease-report.html/toc

Reasons to buy

Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
Analyze the genetic disorders pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at products for the treatment of genetic disorders to provide an insight into the risk associated with attempting to bring pipeline products to market.
Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify commercial opportunities in the genetic disorders deals landscape by analyzing trends in licensing and co-development deals."

List of Table

Table 1: Genetic Disorders, Common Symptoms of Genetic Disorders 14
Table 2: Genetic Disorders, Affected Areas of LSDs 15
Table 3: Genetic Disorders, Classification of Lysosomal Storage Diseases, 2017, Part 1 23
Table 4: Genetic Disorders, Classification of Lysosomal Storage Diseases, 2017, Part 2 25
Table 5: Genetic Disorders, Global, Epidemiology of Genetic Disorders, 2017 27
Table 6: Genetic Disorders, CF Severity Classification, 2017 33
Table 7: Stages of Duchenne Muscular Dystrophy, 2017 35
Table 8: Genetic Disorders, Global, CF Treatment Plan, 2017 38
Table 9: Genetic Disorders, Global, DMD Treatment Plan, 2017 39
Table 10: Genetic Disorders Market, Global, Approved Genetic Disorders Indications for Soliris, 2017 45
Table 11: Genetic Disorders Market, Global, Approved Genetic Disorders Indications for Orkambi, 2017 46
Table 12: Genetic Disorders Market, Global, Approved Genetic Disorders Indications for Cerezyme, 2017 48
Table 13: Genetic Disorders Market, Global, Approved Genetic Disorders Indications for Myozyme/Lumizyme, 2017 50

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1509385

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com

This release was published on openPR.